Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

Ji Yong Jang, Sang Hak Lee, Byung Soo Kim, Hong Seog Seo, Woo Shik Kim, Youngkeun Ahn, Nae Hee Lee, Kwang Kon Koh, Tae Soo Kang, Sang Ho Jo, Bum Kee Hong, Jang Ho Bae, Hyoung Mo Yang, Kwang Soo Cha, Bum Soo Kim, Choong Hwan Kwak, Deok Kyu Cho, Ung Kim, Joo Hee Zo, Duk Hyun KangWook Bum Pyun, Kook Jin Chun, June Namgung, Tae Joon Cha, Jae Hyeon Juhn, Yeili Jung, Yangsoo Jang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalKorean Circulation Journal
Volume45
Issue number3
DOIs
Publication statusPublished - 2015 May 1

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients'. Together they form a unique fingerprint.

  • Cite this

    Jang, J. Y., Lee, S. H., Kim, B. S., Seo, H. S., Kim, W. S., Ahn, Y., Lee, N. H., Koh, K. K., Kang, T. S., Jo, S. H., Hong, B. K., Bae, J. H., Yang, H. M., Cha, K. S., Kim, B. S., Kwak, C. H., Cho, D. K., Kim, U., Zo, J. H., ... Jang, Y. (2015). Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circulation Journal, 45(3), 225-233. https://doi.org/10.4070/kcj.2015.45.3.225